Navigation Links
Coxiella burnetii(Q-Fever) Antibody IgG, Phase I by IFA

ProductsCoxiella burnetii(Q-Fever) Antibody IgG, Phase I by IFA
Company ARUP Laboratories
Item Coxiella burnetii(Q-Fever) Antibody IgG, Phase I by IFA
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Coxiella burnetii (Q-Fever) Antibody IgG, Phase I & II by IFA
2. Coxiellaburnetii (Q-Fever) Antibody IgG, Phase II by IFA
3. Coxiella burnetii Antibody Panel, IFA
4. Coxiella burnetii IgM Antibody, IFA
5. OraQuick ADVANCE Rapid HIV-1/2 Antibody Test
6. Reveal Rapid HIV-1 Antibody Test
7. Wampole PreVue B. Burgdorferi Antibody Detection Assay
8. BioSign® Mono - Rapid Infectious Mononucleosis Heterophile Antibody (IgM) Test
9. OraQuick Rapid HIV-1 Antibody Test
10. FlexSure HP Helicobacter Pylori Antibody Test
11. BioSign® H. pylori - Rapid H. pylori Antibody (IgM/IgG/IgA) Test
Breaking Medicine News(10 mins):Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 3Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 4Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 5Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 2Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 3Health News:Prostate Hormone Therapy May Up Heart Risks 2Health News:Prostate Hormone Therapy May Up Heart Risks 3Health News:New approach to sickle-cell disease shows promise in mice 2
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5OPAXIO 28TM 29 Combined with Alimta 28R 29 Well Tolerated in Dose Ranging Study of Patients with Advanced Non Small Cell Lung Cancer 4808 1OPAXIO 28TM 29 Combined with Alimta 28R 29 Well Tolerated in Dose Ranging Study of Patients with Advanced Non Small Cell Lung Cancer 4808 2OPAXIO 28TM 29 Combined with Alimta 28R 29 Well Tolerated in Dose Ranging Study of Patients with Advanced Non Small Cell Lung Cancer 4808 3Dysport proves safe effective anti wrinkle treatment UT Southwestern plastic surgeons find 53439 1Dysport proves safe effective anti wrinkle treatment UT Southwestern plastic surgeons find 53439 2Beckman Coulter Completes Acquisition of Olympus Lab Based Diagnostics Business 13318 1Beckman Coulter Completes Acquisition of Olympus Lab Based Diagnostics Business 13318 2